GlassScriptPhysician profile
Aracelis Nieves
NPI 1922320217
$3,181.58
in general payments reported to CMS, 2019-2025
17 companies · $804 in 2025
The $804 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $179 · 2021: $357 · 2022: $461 · 2023: $632 · 2024: $297 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $629.67 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $545.57 | 2019-2025 | Eliquis, Reblozyl |
| Abbvie INC. | $444.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $284.50 | 2019-2022 | |
| Pbg Puerto Rico LLC | $255.50 | 2021-2025 | |
| Medtronic, INC. | $223.41 | 2024-2025 | Reveal Linq, Linq II, Interstim |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $205.50 | 2023-2025 | Lifevest |
| Boston Scientific Corporation | $163.12 | 2023 | |
| Merck Sharp & Dohme LLC | $114.03 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $78.09 | 2025 | |
| Lilly USA, LLC | $57.86 | 2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $43.52 | 2022-2024 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $39.28 | 2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $35.80 | 2019-2021 | |
| Bayer Puerto Rico INC. | $23.41 | 2025 | Kerendia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $22.30 | 2019 | |
| Pfizer Pharmaceuticals LLC | $15.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aracelis Nieves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.